Nuvectis Pharma Q1 2025 net loss $5.3M; cash $29.9M; NXP900 Phase 1b advancing

Nuvectis Pharma, Inc.

2025-Q1 EPS reported -$0.27

Cash and equivalents $29.9M as of Mar 31, 2025, up from $18.5M at Dec 31, 2024, driven by $14.0M net public offering proceeds.
Net loss $5.3M for Q1 2025 vs $4.2M in Q1 2024; R&D expenses $3.7M, G&A $1.9M.
NXP900 Phase 1a data at AACR showed robust pharmacodynamic response; Phase 1b enrollment in specific genetic alterations pending.
NXP800 Phase 1b study in ARID1a-mutated ovarian cancer enrolling; update expected in two months.
Completed $15.5M financing extending projected cash runway into Q1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.